Phenotypic Properties in Individuals Affected With XLHED

Related Clinical Trial
Pediatric SARS-CoV-2 Infections: Course of COVID-19, Immune Responses, Complications and Long-term Consequences Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation Characterization of Sweat Gland Function in Patients With Recessively Inherited Hypohidrotic Ectodermal Dysplasia Sweat Duct Imaging in Mother/Newborn Dyads Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey Phenotypic Properties in Individuals Affected With XLHED Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status A Cross-Sectional Natural History Study to Evaluate Sweat Volume and Other Phenotypic and Genetic Characteristics in Patients Affected by XLHED A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200 Investigation of Chronic Inflammatory Processes in Male Individuals With Hypohidrotic Ectodermal Dysplasia Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012) Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002 Short Term Effects and Risks of Physical Exercise in Subjects With Hypohidrotic Ectodermal Dysplasia Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia – A

Brief Title

Phenotypic Properties in Individuals Affected With XLHED

Official Title

Phenotypic Properties in Individuals Affected With X-linked Hypohidrotic Ectodermal Dysplasia: Symptoms and Facial Recognition

Brief Summary

      The current study design incorporates two previously developed, non-invasive approaches to
      characterize the phenotype of individuals affected with XLHED.
    

Detailed Description

      The current study design incorporates two previously developed, non-invasive approaches to
      characterize the phenotype of individuals affected with XLHED. Facial 3-dimensional (3D)
      imaging will be created from white-field morphometric scanning (Hammond, 2004. The 3D facial
      photographs collected from males (ages 4 years and up) will be used to develop a non-invasive
      screening tool, which could enable detection of craniofacial signs of XLHED in the newborn
      period. 3D facial profiling has been reported to be effective in identifying HED (Dellavia et
      al., 2008), but the technology does not yet meet the ease-of-use criteria for a universal
      screening tool.

      Standard 2-dimensional (2D) frontal and lateral facial photographs will be taken of the same
      XLHED-affected male subjects as well as of adult females (ages 18-45 yrs) at risk for being
      XLHED carriers and unaffected adult female controls. The 2D facial photographs will serve a
      dual purpose; the first being to beta-test a previously developed algorithm to identify males
      affected with XLHED (Automatic Phenotype Identification of XLHED Patients Final Report,
      December 25, 2012, unpublished), and the second to adapt the facial recognition algorithm to
      identify female carriers of XLHED.
    


Study Type

Observational


Primary Outcome

To collect demographic and clinical status information in XLHED-affected males, adult females at risk for XLHED and adult female controls


Condition

X Linked Hypohidrotic Ectodermal Dysplasia


Study Arms / Comparison Groups

 XLHED affected Males
Description:  All males ages 4 and up affected by XLHED

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

30

Start Date

May 2013

Completion Date

September 2013

Primary Completion Date

July 2013

Eligibility Criteria

        Inclusion Criteria:

          1. Females of original gender of age 18-45 years who are registered and attending the
             2013 NFED Family Conference. This will include those at risk for XLHED and controls

          2. XLHED-affected males of original gender of age 4 yrs and up who are registered and
             attending the 2013 NFED Family Conference

          3. Provide informed consent/assent

        Exclusion Criteria:

          1. Subjects who are not able or are not willing to comply with the procedures of this
             protocol

          2. Subjects with any major medical problem that will prevent them from participating in
             this study

          3. Male subjects who participated in the prior study ECP-003 sponsored by Edimer
             Pharmaceuticals Inc. in May 2011 in San Francisco, CA

          4. Males at risk for XLHED with prior genetic testing that did not reveal an EDA mutation
      

Gender

All

Ages

4 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Dorothy K Grange, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01871714

Organization ID

ECP-014


Responsible Party

Sponsor

Study Sponsor

Edimer Pharmaceuticals


Study Sponsor

Dorothy K Grange, MD, Principal Investigator, Washington University School of Medicine


Verification Date

November 2013